APELLIS PHARMACEUTICALS INC (APLS)

US03753U1060 - Common Stock

39.67  +0.84 (+2.16%)

After market: 39.5 -0.17 (-0.43%)

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (9/28/2023, 5:32:56 PM)

After market: 39.5 -0.17 (-0.43%)

39.67

+0.84 (+2.16%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)07-31 2023-07-31/bmo
Earnings (Next)11-06 2023-11-06/amc
Ins Owners2.14%
Inst Owners90.65%
Market Cap4.67B
Shares117.74M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80.95
IPO11-09 2017-11-09
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

APLS Daily chart

Company Profile

Apellis Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company is headquartered in Waltham, Massachusetts and currently employs 767 full-time employees. The company went IPO on 2017-11-09. The firm is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.

Company Info

APELLIS PHARMACEUTICALS INC

100 Fifth Avenue

Waltham MASSACHUSETTS 02451

P: 16179775700.0

CEO: Cedric Francois

Employees: 767

Website: https://apellis.com/

APLS Twits

Here you can normally see the latest stock twits on APLS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example